Farmhispania Group
Farmhispania Group is a privately held Spanish CDMO and generic API manufacturer founded in 1974, operating two GMP FDA-inspected sites in Montmeló and Zaragoza. It specializes in HPAPIs, high-potency fermentation, and antibody-drug conjugates, supplying global pharmaceutical companies with regulatory-cleared APIs and contract manufacturing services.
- Company typePrivate
- Founded1974
- HeadquartersBarcelona, Spain
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Farmhispania Group does
Farmhispania Group is a privately held Spanish pharmaceutical company founded in 1974, operating as a leading European Contract Development and Manufacturing Organization (CDMO) and supplier of generic Active Pharmaceutical Ingredients (APIs). The group comprises three co-responsible legal entities headquartered in Montmeló, Barcelona, with a second manufacturing site in Zaragoza operated through its wholly-owned subsidiary Rolabo Outsourcing, S.L. Its core technology centers on the manufacture of highly potent active pharmaceutical ingredients (HPAPIs), high-potency fermentation for biomolecules, and development of antibody-drug conjugates (ADCs) for oncology applications, supported by five R&D laboratories and more than 60 scientists.
The company generates revenue through two streams: long-term contract development and manufacturing services (CDMO) sold directly to pharmaceutical clients, and product sales of generic APIs under regulatory approvals including CEP, FDA, and ANVIA. Customer acquisition is driven by a dedicated Business Development unit, direct commercial outreach, and participation at major industry trade shows (CPhI, DCAT, BioEurope). Its customer base consists of pharmaceutical companies requiring regulatory-compliant, high-containment API manufacturing and supply continuity for critical medicines, with Merck & Co. (MSD) identified as a recognized long-term partner.
Farmhispania's competitive position rests on a multi-jurisdictional regulatory record (five consecutive FDA inspections since 2006 with zero observations, plus ANVISA, PMDA, KFDA, and Russian Health Authority clearances), possession of the world's first EDQM CEP for Everolimus 2% BHT, and a recently expanded Montmeló facility featuring a new 8-floor, 3,200 m² multipurpose manufacturing building. The company is actively investing in ESG positioning (SBTi-approved targets, UN Global Compact membership) and capabilities in ADCs and biomolecules as next-generation growth vectors.
Farmhispania Group firmographics
Firmographics- Name
- Farmhispania Group
- Legal name
- FARMHISPANIA, S.A., FARMHISPANIA GROUP, S.L. and ROLABO OUTSOURCING, S.L.
- Website
- https://farmhispaniagroup.com
- Company type
- Private
- Founded year
- 1974
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Farmhispania Group is a privately held Spanish CDMO and generic API manufacturer founded in 1974, operating two GMP FDA-inspected sites in Montmeló and Zaragoza. It specializes in HPAPIs, high-potency fermentation, and antibody-drug conjugates, supplying global pharmaceutical companies with regulatory-cleared APIs and contract manufacturing services.
- Ownership category
- akta.pro rank
Farmhispania Group industry classification
Industry- Product category
- Pharmaceutical API Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule API Commercial Manufacturing (HLAGAHAB)
- akta.pro secondary industries
- High-Potency API (HPAPI) Development & Manufacturing (HLAGAHAC), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where Farmhispania Group is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Farmhispania Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- CDMO (Contract Development and Manufacturing Services): Contract manufacturing services for pharmaceutical companies requiring development and production of APIs, including HPAPI and fermentation-based products. Services include process development, scale-up, and GMP manufacturing under long-term contracts with pharmaceutical clients.
- Generic Active Pharmaceutical Ingredients (APIs): Manufacture and sale of generic APIs to pharmaceutical companies worldwide. Revenue is generated through product sales under established regulatory approvals (CEP, FDA, ANVISA).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B contract manufacturing and generic API supply — pricing negotiated per engagement. |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Farmhispania Group product offering
Product offeringCore offering
Farmhispania Group manufactures and sells Active Pharmaceutical Ingredients (APIs), including generic APIs such as Metformin HCl, and provides Contract Development and Manufacturing Organization (CDMO) services for pharmaceutical companies. The company specializes in High Potency Active Pharmaceutical Ingredients (HPAPIs), high-potency fermentation-based biomolecule production, and antibody-drug conjugate (ADC) synthesis process development. Manufacturing is conducted at two GMP-compliant, FDA-inspected production sites in Spain, with research and process development supported by five R&D laboratories and more than 60 scientists.
Product overview
Farmhispania Group is a leading European CDMO (Contract Development and Manufacturing Organization) specializing in Active Pharmaceutical Ingredients (APIs). The company operates two GMP FDA-inspected manufacturing sites in Spain (Montmeló-Barcelona and Zaragoza) and offers an integrated portfolio comprising: CDMO services for custom development and manufacturing, Generic APIs (including Metformin HCl), HPAPI (Highly Potent Active Pharmaceutical Ingredients) technologies, and Fermentation capabilities for biologics. Key products include Everolimus 2% BHT (first CEP issued worldwide) and ADC (Antibody-Drug Conjugates) for cancer therapy. The company leverages 5 R&D laboratories with over 60 scientists to support its manufacturing operations.
Differentiator
Problem solved
Functional benefit
Products and services
- CDMO (Contract Development and Manufacturing Organization) Services End-to-end contract development and manufacturing services for active pharmaceutical ingredients, offering R&D, process development, scale-up, and GMP-compliant commercial production to pharmaceutical companies requiring external manufacturing partners.
- Generic APIs (Active Pharmaceutical Ingredients) Generic Active Pharmaceutical Ingredients, including Metformin HCl, manufactured under GMP conditions for sale to pharmaceutical companies worldwide under established regulatory approvals (CEP, FDA DMF, ANVISA).
- HPAPI (Highly Potent Active Pharmaceutical Ingredients) Manufacturing Specialized manufacturing of Highly Potent Active Pharmaceutical Ingredients for oncology and other targeted therapies requiring specialized containment, handling, and regulatory-grade production capabilities.
- High Potency Fermentation Services Fermentation-based manufacturing services for the production of biologics, biomolecules, and biological entities for therapeutic and diagnostic applications in humans.
- Everolimus 2% BHT API Everolimus 2% BHT, an Active Pharmaceutical Ingredient for which Farmhispania Group received the first-ever Certificate of Suitability (CEP) from EDQM, making it the first company worldwide to hold a CEP for Everolimus.
- ADC (Antibody-Drug Conjugate) Development and Synthesis Optimization Development and optimization of synthesis processes for therapeutic monoclonal antibodies conjugated to cytotoxic chemical drugs (ADCs), used in targeted cancer therapy applications.
Quantifiable outcome
- First CEP for Everolimus 2% BHT issued by EDQM — first time a CEP for Everolimus has been issued to any company.
Companies that use Farmhispania Group
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Farmhispania Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Farmhispania Group partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- UN Global CompactcoreFarmhispania Group formally joined the United Nations Global Compact in May 2026, committing to the UN's ten principles covering human rights, labour, environment, and anti-corruption.
- Science Based Targets initiative (SBTi)coreFarmhispania Group received approval of its Science Based Targets (SBTs) by the Science Based Targets initiative in April 2025, committing to science-aligned greenhouse gas emission reduction targets.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Farmhispania Group competitors and assessment
Company assessmentDirect peers
- Carbogen Amcis: Swiss CDMO with strong HPAPI and ADC development capabilities. Direct peer in high-potency API manufacturing and antibody-drug conjugate process development for global pharma customers.
- Hovione: Portuguese-headquartered CDMO specializing in HPAPI, particle engineering, and API manufacturing with multiple FDA-inspected sites. Directly comparable as a European HPAPI and contract API CDMO serving global pharma.
- Olon Group: Italian CDMO and generic API manufacturer with fermentation and HPAPI capabilities. Highly comparable to Farmhispania on European generic API supply plus CDMO services for HPAPI and biologics.
- PharmaZell (formerly Novasep CDMO): European API manufacturer with HPAPI and complex chemistry capabilities. Comparable as a European mid-sized API specialist competing for similar HPAPI and small-molecule CDMO contracts.
Broad incumbents
- Recipharm: Swedish-headquartered CDMO with broad API and finished dose services across Europe. Comparable as a larger European CDMO with overlapping generic and contract API offerings.
- EUROAPI: European API specialist spun out of Sanofi with broad small-molecule and HPAPI capabilities. Comparable as a Europe-based commercial API manufacturer with CDMO ambitions overlapping Farmhispania's offerings.
- Aenova Group: German pharmaceutical CDMO with API and finished dose capabilities. Comparable as a European mid-market CDMO serving global pharma with similar scale and regulatory footprint.
- Johnson Matthey (Pharma Services / Particle Sciences): Global specialty chemicals group with an HPAPI and drug development CDMO business. Comparable as a larger incumbent offering HPAPI and complex API services with global scale.
- Siegfried Holding: Swiss-listed CDMO with broad API and finished dose manufacturing services across multiple sites. Comparable as a larger European CDMO competitor with overlapping API manufacturing capabilities.
- CordenPharma: European CDMO offering APIs, peptides, lipids, and injectables manufacturing. Comparable as a larger, more diversified CDMO competing for HPAPI and complex API programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Farmhispania Group social profiles
Digital presenceFarmhispania Group compliance and trust
Trust signalCompliance11 records
Farmhispania Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Farmhispania Group leadership team
Management profileNumber of profiles
Profiles1 record
Farmhispania Group subsidiaries and ownership
Company hierarchySubsidiaries1 record
Farmhispania Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Farmhispania Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Farmhispania Group
What does Farmhispania Group do?
Farmhispania Group manufactures and sells Active Pharmaceutical Ingredients (APIs), including generic APIs such as Metformin HCl, and provides Contract Development and Manufacturing Organization (CDMO) services for pharmaceutical companies. The company specializes in High Potency Active Pharmaceutical Ingredients (HPAPIs), high-potency fermentation-based biomolecule production, and antibody-drug conjugate (ADC) synthesis process development. Manufacturing is conducted at two GMP-compliant, FDA-inspected production sites in Spain, with research and process development supported by five R&D laboratories and more than 60 scientists.
Is Farmhispania Group a public or private company?
Farmhispania Group is a private company. It is classified as private equity controlled and is currently operating.
When was Farmhispania Group founded?
Farmhispania Group was founded in 1974. It employs 251 to 500 people.
Where is Farmhispania Group based?
Farmhispania Group is headquartered in Barcelona, Spain, in the Europe region.
How does Farmhispania Group make money?
Two revenue lines are on record. CDMO (Contract Development and Manufacturing Services) is the primary driver. The others are generic Active Pharmaceutical Ingredients (APIs).
Who are Farmhispania Group's main competitors?
Direct peers on record are Carbogen Amcis, Hovione, Olon Group and PharmaZell (formerly Novasep CDMO). Broad incumbents are Recipharm, EUROAPI, Aenova Group, Johnson Matthey (Pharma Services / Particle Sciences), Siegfried Holding and CordenPharma.
Does Farmhispania Group have an API?
No public API is recorded for Farmhispania Group.
What industry is Farmhispania Group in?
Farmhispania Group's product category is Pharmaceutical API Manufacturing. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAGAHAC, High-Potency API (HPAPI) Development & Manufacturing. Its NAICS code is 32541 and its SIC code is 2834.